South Korea’s GC Biopharma partners with Novelty Nobility

28 October 2024

Yongyin-based biopharma company GC Biopharma (KOSPI: 006280) has announced a partnership with Novelty Nobility for the joint development of a new treatment for geographic atrophy (GA).

GA is a leading cause of blindness in older adults, due to an advanced dry form of age-related macular degeneration (AMD). The condition, which affects around 1.5 million people in the USA, leads to retinal tissue damage and vision loss.

The collaboration seeks to address the limitations of current GA treatments, which have only shown partial efficacy in slowing disease progression and carry risks of adverse side effects.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK